C. Codding

发表

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

M. Dougados, M. Schiff, M. Schiff, 2007, Annals of the rheumatic diseases.

Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee.

G. Torrance, D. Marshall, C. Codding, 2006, The American journal of managed care.

(248) Analgesic efficacy and safety of controlled-release hydrocodone and acetaminophen tablets, dosed twice daily, for moderate to severe mechanical chronic low-back pain: A randomized, double-blind, placebo-controlled withdrawal trial

E. Lockhart, C. Codding, M. Hale, 2008 .

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

S. Agarwal, A. Deodhar, C. Bingham, 2010, Arthritis and rheumatism.

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

M. Genovese, P. Durez, Sang-Heon Lee, 2014, The Journal of Rheumatology.

Differences in the fine specificity of anti-Ro (SS-A) in relation to the presence of other precipitating autoantibodies.

C. Codding, M. Reichlin, M. Rader, 1989, Arthritis and rheumatism.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

U. Wagner, A. Gottlieb, A. Orbai, 2017, The Lancet.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Patrick Durez, M. Genovese, V. Mazurov, 2012, Annals of the rheumatic diseases.

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

F. Blanco, C. Codding, H. Richards, 2017, Arthritis & rheumatology.

Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial.

F. Burch, C. Codding, E. Sheldon, 2004, Osteoarthritis and cartilage.

Tubulointerstitial nephritis due to vancomycin.

J. Pitha, C. Codding, M. Allon, 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

I. McInnes, C. Delles, N. Sattar, 2013, Annals of the rheumatic diseases.

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

M. Genovese, M. Cardiel, A. Kivitz, 2017, Arthritis & rheumatology.

M. Dougados, C. Poncet, M. Schiff, 2022 .

Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis

B. Galer, A. Gammaitoni, F. Burch, 2004, Current medical research and opinion.

Aseptic meningitis in association with diclofenac treatment in a patient with systemic lupus erythematosus.

I. Targoff, C. Codding, G. Mccarty, 1991, Arthritis and rheumatism.

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

M. Dougados, C. Poncet, M. Schiff, 2011, Annals of the Rheumatic Diseases.